国产培美曲塞治疗进展性非小细胞肺癌近期疗效分析  

Analysis of short-term efficacy of domestic pemetrexed in treatment of advanced non-small-cell lung carcinoma

作　　者：张凌云[1] 黄亚平[1] 易铁男[1] 

机构地区：[1]华中科技大学同济医学院附属襄樊医院,湖北襄樊441021

出　　处：《中国肿瘤临床与康复》2010年第5期461-462,465,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的回顾性分析国产培美曲塞(普来乐)治疗进展性非小细胞肺癌(NSCLC)的近期疗效性和毒副反应。方法 24例经组织学及细胞学证实的晚期进展的NSCLC患者,使用国产培美曲塞单药治疗,500mg/m2,静脉滴入,d1,21d为1个周期,连用2～4个周期,进行疗效及毒副反应评价。结果 24例均可评价疗效,CR0例,PR3例,PD8例,SD13例;有效率(RR)为12.5%(3/24),疾病控制率(DCR)为45.8%(11/24)。毒副反应主要表现为轻到中度胃肠道反应和骨髓抑制。结论国产培美曲塞治疗晚期进展性NSCLC具有较好的疗效且毒副反应轻。Objective To analyze retrospectively the short-term efficacy and side effect of domestic pemetrexed in treatment of advanced non-small-cell lung carcinoma（ NSCLC） . Methods Twenty-four patients with NSCLC confirmed by histopathology and/or cytology were treated with single pemetrexed intrave-nously guttae 500 mg/m2 d1,one cycle consisted of 21 days,a total of four cycles,then therapeutic and side effects were evaluated. Results All 24 patients were evaluable. No one reached complete response,partial response was observed in 3 cases,progressive disease in 8 cases,stable disease 13 cases,response rate （ RR） was 12. 5% （ 3/24） ,disease control rate（ DCR） was 45. 8% （ 11/24） . The main side effects were slight to moderate gastrointestinal reaction and bone marrow suppression. Conclusions Domestic pemetrexed has good therapeutic efficacy in patients with NSCLC,and side effect is tolerable and mild.

关 键 词：国产培美曲塞 肺肿瘤 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]